Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
 
Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
  
 
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530 
     free
  
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531 
     free
      free 
   English Wikipedia
  Nephropedia Template TP (
  Twit Text
 
  DeepDyve Pubget Overpricing |    
 
  lüll A longitudinal study to identify laboratory predictors of liver disease outcome  in Alagille syndrome Kamath BM; Munoz PS; Bab N; Baker A; Chen Z; Spinner NB; Piccoli DAJ Pediatr Gastroenterol Nutr  2010[May]; 50 (5): 526-30OBJECTIVES: Liver disease in Alagille syndrome (AGS) is highly variable, ranging  from biochemical abnormalities only to end-stage disease. It is not possible to  predict whether a child with cholestasis will have improvement or progression of  liver disease. This poses a challenge to the clinician in terms of timing  therapies. The study aim was to identify laboratory markers present in children  younger than 5 years that could predict the ultimate outcome of liver disease in  AGS. METHODS: A retrospective review of laboratory data from 33 subjects with AGS  was performed. Patients older than 10 years of age were stratified into mild (22)  and severe (11) hepatic outcome groups. Nonparametric analysis was performed on  longitudinal data from birth to 5 years to determine association with hepatic  outcome. JAGGED1 mutational analysis was performed on available samples. RESULTS:  The following variables were statistically different between severe and mild  outcome groups: total bilirubin (TB, P = 0.0001), conjugated bilirubin (CB, P =  0.0066), and cholesterol (P = 0.0022). Further analysis revealed cutoff values  that differentiated between severe and mild outcomes; TB 6.5 mg/dL (111  micromol/L), CB 4.5 mg/dL (77 micromol/L), and cholesterol 520 mg/dL (13.5  mmol/L). Genetic analysis of JAGGED1 mutations did not reveal genotype-phenotype  correlation. CONCLUSIONS: TB >6.5 mg/dL, CB >4.5 mg/dL, and cholesterol >520  mg/dL in children younger than 5 years of age are likely to be associated with  severe liver disease in later life. These data represent cutoff values below  which a child is likely to have a benign outcome and above which more aggressive  therapy may be warranted, and can thus be used to guide management.|Alagille Syndrome/*blood/genetics[MESH]|Bilirubin/*blood[MESH]|Biomarkers/blood[MESH]|Calcium-Binding Proteins/genetics[MESH]|Child[MESH]|Child, Preschool[MESH]|Cholesterol/*blood[MESH]|Disease Progression[MESH]|Genotype[MESH]|Humans[MESH]|Infant[MESH]|Intercellular Signaling Peptides and Proteins/genetics[MESH]|Jagged-1 Protein[MESH]|Liver Diseases/blood/*etiology/genetics[MESH]|Longitudinal Studies[MESH]|Membrane Proteins/genetics[MESH]|Mutation[MESH]|Phenotype[MESH]|Prognosis[MESH]|Reference Values[MESH]|Retrospective Studies[MESH]|Serrate-Jagged Proteins[MESH]|Severity of Illness Index[MESH] |